Lucas Lopez
@graemearchie
SanegeneBio and Innovent Biologics have successfully administered the first patient in the Phase I clinical trial of SGB-3908. This siRNA drug targets angiotensinogen (AGT) and is being developed for the treatment of hypertension. #QMPortfolio
0 reply
0 recast
0 reaction